What are the recommended dosing and duration of oseltamivir (Tamiflu) for treating and preventing influenza in adults and children?

Tamiflu Dosing and Duration

For adults and adolescents ≥13 years: oseltamivir 75 mg twice daily for 5 days for treatment, or 75 mg once daily for at least 10 days for prophylaxis; for children ≥1 year: weight-based dosing (30-75 mg) twice daily for treatment or once daily for prophylaxis. 1

Treatment Dosing

Adults and Adolescents (≥13 years)

• 75 mg twice daily for 5 days 1
• Must initiate within 48 hours of symptom onset 1
• Can be taken with or without food, though taking with food may reduce gastrointestinal side effects 1

Pediatric Patients (≥1 year)

Weight-based dosing twice daily for 5 days 1:

• ≤15 kg (≤33 lbs): 30 mg twice daily
• 16-23 kg (34-51 lbs): 45 mg twice daily
• 24-40 kg (52-88 lbs): 60 mg twice daily
• >40 kg (>88 lbs): 75 mg twice daily

Infants (<1 year)

Not FDA-approved, but CDC provides emergency dosing recommendations 2:

• 3-11 months: 3 mg/kg/dose twice daily for treatment
• <3 months: 3 mg/kg/dose twice daily for treatment (WHO recommends once daily for infants <14 days) 2

Critical timing consideration: Treatment initiated within 12 hours of symptom onset provides an additional 74.6 hours of symptom reduction compared to treatment at 48 hours; within 24 hours provides an additional 53.9 hours of benefit 3. This underscores the importance of early initiation.

Prophylaxis Dosing

Post-Exposure Prophylaxis (Following Close Contact)

Adults and Adolescents (≥13 years):

• 75 mg once daily for at least 10 days 1
• Must begin within 2 days of exposure 1

Pediatric Patients (≥1 year):

• Same weight-based doses as treatment, but once daily for 10 days 1
• Must begin within 2 days of exposure

Community Outbreak Prophylaxis

Adults and Adolescents:

• 75 mg once daily 1
• Duration: up to 6 weeks in immunocompetent patients 1
• Up to 12 weeks demonstrated safe in immunocompromised patients 1

Pediatric Patients (≥1 year):

• Same weight-based doses once daily
• May continue up to 6 weeks during community outbreak 1

Renal Impairment Adjustments

For creatinine clearance 10-30 mL/min 1:

• Treatment: 75 mg once daily for 5 days
• Prophylaxis: 75 mg every other day OR 30 mg once daily

No established dosing for end-stage renal disease on dialysis 1.

Important Clinical Caveats

Efficacy window: Oseltamivir only works during viral replication phase. No clinical benefit demonstrated when started >48 hours after symptom onset 1, 3. The earlier treatment begins within this window, the greater the benefit.

Not a vaccine substitute: Oseltamivir prophylaxis does not replace annual influenza vaccination 1. Protection only lasts as long as dosing continues 1.

Pediatric clearance: Children 1-12 years eliminate the active metabolite faster than adolescents and adults, necessitating the higher weight-based dosing (approximately 2 mg/kg) to achieve therapeutic drug levels 4.

Formulation options: For patients unable to swallow capsules, oral suspension is preferred. If unavailable, capsules may be opened and mixed with sweetened liquids (chocolate syrup, corn syrup, caramel topping, or dissolved brown sugar) 1.

Tolerability: Nausea (10-15%) and vomiting (2-3%) are most common adverse effects, typically mild and transient, resolving within 1-2 days 3, 5. Taking with food significantly reduces these symptoms 1, 3.